Contra-indicated during episodes of hypoglycemia.
Ryzodeg is insulin degludec and insulin aspart; Xultophy is insulin degludec and liraglutide; various forms of insulin are available - see other insulin profiles for reaction details.
- TRADE NAMES: Ryzodeg (Novo Nordisk); Tresiba (Novo Nordisk); Xultophy (Novo Nordisk)
- INDICATIONS: Diabetes mellitus
- CLASS: Human insulin analog, long-acting
- HALF-LIFE: 25 hours
- FDA APPROVAL DATE: 07/25/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
ACE inhibitors, Albuterol, Alcohol, Angiotensin II receptor blocking agents, Beta blockers, Clonidine, Clozapine, Corticosteroids, Danazol, DDP-4-inhibitors, Disopyramide, Diuretics, Epinephrine, Estrogens, Fibrates, Fluoxetine, GLP-1 receptor agonists, Glucagon, Guanethidine, Isoniazid, Lithium, MAO inhibitors, Niacin, Octreotide, Olanzapine, Oral Contraceptives, Pentamidine, Pentoxifylline, Phenothiazines, Pramlintide, Propoxyphene, Protease inhibitors, Reserpine, Salicylates, SGLT-2 inhibitors, Somatropin, Sulfonamide antibiotics, Terbutaline, Thyroid hormones
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
